{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443837353
| ImageFile = Glisoxepide.svg
| ImageSize = 275
| ImageFile1 = Glisoxepide molecule ball.png
| ImageSize1 = 275
| IUPACName = ''N''-[2-[4-(azepan-1-ylcarbamoylsulfamoyl)<wbr />phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide
| OtherNames =

| Section1 = {{Chembox Identifiers
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 30380
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = H7SC0I332I
| InChI = 1/C20H27N5O5S/c1-15-14-18(23-30-15)19(26)21-11-10-16-6-8-17(9-7-16)31(28,29)24-20(27)22-25-12-4-2-3-5-13-25/h6-9,14H,2-5,10-13H2,1H3,(H,21,26)(H2,22,24,27)
| InChIKey = ZKUDBRCEOBOWLF-UHFFFAOYAG
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H27N5O5S/c1-15-14-18(23-30-15)19(26)21-11-10-16-6-8-17(9-7-16)31(28,29)24-20(27)22-25-12-4-2-3-5-13-25/h6-9,14H,2-5,10-13H2,1H3,(H,21,26)(H2,22,24,27)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZKUDBRCEOBOWLF-UHFFFAOYSA-N
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo = 25046-79-1
| PubChem = 32778
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2106618
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07118
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01289
| SMILES = O=C(NCCc1ccc(cc1)S(=O)(=O)NC(=O)NN2CCCCCC2)c3noc(c3)C
}}

| Section2 = {{Chembox Properties
| Formula = C<sub>20</sub>H<sub>27</sub>N<sub>5</sub>O<sub>5</sub>S
| MolarMass = 449.52388 g/mol
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility =
  }}

|Section6 = {{Chembox Pharmacology
| ATCCode_prefix = A10
| ATCCode_suffix = BB11
}}

|Section7={{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt =
  }}
}}

'''Glisoxepide''' ([[International Nonproprietary Name|INN]]) is an orally available [[anti-diabetic drug]] from the group of [[sulfonylurea]]s.<ref>{{cite journal |vauthors=Haupt E, Köberich W, Beyer J, Schöffling K |title=Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. I. Dose response relations and repeated administration in diabetic subjects |journal=Diabetologia |volume=7 |issue=6 |pages=449–54 |date=December 1971 |pmid=5004178 |doi=10.1007/bf01212061}}</ref> It belongs to second-generation sulfonylureas.<ref>{{cite journal|last1=Loubatières|first1=A|last2=Ribes|first2=G|last3=Mariani|first3=MM|last4=Alric|first4=R|title=Pharmacological Comparison Between Tolbutamide and Two Second Generation Hypoglycemic Sulfonylureas (Glibenclamide and Glisoxepide)|journal=Acta diabetologica latina|volume=10|issue=2|pages=261–82|pmid=4200420|doi=10.1007/bf02590661|year=1973}}</ref>

==References==
{{Reflist}}

{{Oral hypoglycemics and insulin analogs}}
{{Ion channel modulators}}

[[Category:Potassium channel blockers]]
[[Category:Azepanes]]
[[Category:Carboxamides]]
[[Category:Isoxazoles]]
[[Category:Sulfonylureas]]
[[Category:Ureas]]

{{gastrointestinal-drug-stub}}